Sartorius Stedim Biotech (FR:DIM)
:DIM
Want to see FR:DIM full AI Analyst Report?
Total Valuation
Sartorius Stedim Biotech has a market cap or net worth of €15.80B. The enterprise value is €17.88B.
Market Cap€15.80B
Enterprise Value€17.88B
Share Statistics
Sartorius Stedim Biotech has 97,330,410 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding97,330,410
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Sartorius Stedim Biotech’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.44%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)5.44%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee297.91K
Profits Per Employee26.66K
Employee Count9,961
Asset Turnover0.37
Inventory Turnover2.35
Valuation Ratios
The current PE Ratio of Sartorius Stedim Biotech is 45.9. Sartorius Stedim Biotech’s PEG ratio is 1.51.
PE Ratio45.9
PS Ratio6.89
PB Ratio5.00
Price to Fair Value5.00
Price to FCF140.53
Price to Operating Cash Flow25.87
PEG Ratio1.51
Income Statement
In the last 12 months, Sartorius Stedim Biotech had revenue of 2.97B and earned 265.60M in profits. Earnings per share was 2.73.
Revenue2.97B
Gross Profit1.35B
Operating Income549.00M
Pretax Income373.20M
Net Income265.60M
EBITDA867.10M
Earnings Per Share (EPS)2.73
Cash Flow
In the last 12 months, operating cash flow was 610.50M and capital expenditures -397.50M, giving a free cash flow of 213.00M billion.
Operating Cash Flow610.50M
Free Cash Flow213.00M
Free Cash Flow per Share2.19
Dividends & Yields
Sartorius Stedim Biotech pays an annual dividend of €0.69, resulting in a dividend yield of 0.31%
Dividend Per Share€0.69
Dividend Yield0.31%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.35
52-Week Price Change-18.76%
50-Day Moving Average171.80
200-Day Moving Average186.90
Relative Strength Index (RSI)65.72
Average Volume (3m)78.09K
Important Dates
Sartorius Stedim Biotech upcoming earnings date is Jul 16, 2026, Before Open (Confirmed).
Last Earnings DateApr 23, 2026
Next Earnings DateJul 16, 2026
Ex-Dividend Date―
Financial Position
Sartorius Stedim Biotech as a current ratio of 1.02, with Debt / Equity ratio of 63.64%
Current Ratio1.02
Quick Ratio0.53
Debt to Market Cap0.13
Net Debt to EBITDA2.68
Interest Coverage Ratio3.60
Taxes
In the past 12 months, Sartorius Stedim Biotech has paid 107.30M in taxes.
Income Tax107.30M
Effective Tax Rate0.29
Enterprise Valuation
Sartorius Stedim Biotech EV to EBITDA ratio is 26.25, with an EV/FCF ratio of 156.51.
EV to Sales7.67
EV to EBITDA26.25
EV to Free Cash Flow156.51
EV to Operating Cash Flow42.25
Balance Sheet
Sartorius Stedim Biotech has €521.20M in cash and marketable securities with €2.61B in debt, giving a net cash position of -€2.09B billion.
Cash & Marketable Securities€521.20M
Total Debt€2.61B
Net Cash-€2.09B
Net Cash Per Share-€21.51
Tangible Book Value Per Share-€3.03
Margins
Gross margin is 44.71%, with operating margin of 18.50%, and net profit margin of 8.95%.
Gross Margin44.71%
Operating Margin18.50%
Pretax Margin12.58%
Net Profit Margin8.95%
EBITDA Margin29.22%
EBIT Margin18.50%
Analyst Forecast
The average price target for Sartorius Stedim Biotech is €233.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€233.00
Price Target Upside23.48% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast4.43%
EPS Growth Forecast31.23%